Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Metastatic Breast Cancer
Clinical trial register · United Kingdom · industry-sponsored

Metastatic Breast Cancer Trials in the UK, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 12 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 10 Manchester 5 Nottingham 5 Cardiff 4 Leeds 3
Narrow the registerReset
Recruitment status
Phase
Site city
London10 Manchester5 Nottingham5 Cardiff4 Leeds3
All 31 cities
Target enrolment
to

Metastatic Breast Cancer trials in the UK

12 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brighton, London, Taunton, Guildford, Cardiff
2025-11-03
Recruiting
BioNTech SE
Phase 1/2
380
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
2025-04-23
Active, closed
Merck Sharp & Dohme LLC
Phase 2
120
Truro, London, Withington, Ipswich
2024-11-27
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
2024-06-28
Active, closed
DualityBio Inc.
Phase 3
541
Truro, London, Southampton, Manchester, Maidstone, Middlesex, Nottingham, Bath
2024-01-18
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Recruiting
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Recruiting
Hoffmann-La Roche
Phase 3
230
Belfast, Blackpool, Colchester, Essex, Northwood, Nottingham, Oxford
2023-09-08
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
Liverpool, London
2023-01-24
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Ellipses Pharma
Phase 1/2
95
London, Manchester, Liverpool
2023-01-11
Active, closed
AstraZeneca
Phase 1/2
245
Buckhurst Hill
2020-12-28
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-uk/condition/metastatic-breast-cancer

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 12 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Metastatic Breast Cancer.

How many Metastatic Breast Cancer trials are recruiting in the UK?

7 of the 12 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metastatic Breast Cancer), 12 studies
PhaseStudiesRecruitingShare
Phase 1/26450%
Phase 35341.7%
Phase 2108.3%

Most active sponsors

Lead sponsors with the most studies (Metastatic Breast Cancer)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche22
Olema Pharmaceuticals, Inc.21
AstraZeneca10
BioNTech SE11
Boehringer Ingelheim11
DualityBio Inc.10
Ellipses Pharma11
LeonaBio11
Merck Sharp & Dohme LLC10
Stemline Therapeutics, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.